Situation: Sales/prospecting teams needed a defensible way to prioritize emerging pharma accounts from noisy public sources, unverified research sites, and scattered trial activity—without manual research or bloated vendor databases.

What I built: Automated prospecting system extracting clinical trial data from ClinicalTrials.gov. Multi-factor scoring model evaluating emerging pharma companies on financial metrics, team composition, and pipeline activity. Prioritized account list delivered with executive contacts and composite scores for sales targeting.
Outcome: Faster, defensible targeting with testable weighting and filters (by vertical, geography, or funding stage), easy refresh cadence, and portfolio visibility.